The epidemic of COVID-19, which threatened the mass, globally, was brought on by the newly discovered corona virus, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). The SARS-CoV-2 that caused COVID-19 has posed serious risks to people’s health, public safety and the world’s economy. Worldwide, considerable and quick research on pharmacological therapy is being conducted as a result of the COVID-19 pandemic. The particular characteristics of the metal centers now employed in medicinal chemistry make metallodrugs a good candidate for achieving the treatment objective. Here two key approaches are discussed for creating metal-based medicines that successfully combat SARS-CoV-2. A “Drug Repurposing” strategy and a “Discovery Approach” motivated by a pathway and based on prior knowledge may help. Selectivity and toxicity problems need to be taken into consideration while using metal compounds. Metal-related medications have long been used as antiviral medications and enzyme inhibitors, offering possible treatments for COVID-19. These display a broad range of bioactivities, showcasing incomparable advantages in pharmacology. For the SARS-CoV-2 infection, it is well established that metallodrugs play a significant role in direct antiviral therapy or in the inhibition of essential viral replication-related enzymes. They can also be used as vaccine adjuvant or as pharmaceuticals to boost the effectiveness of antiviral medications (like zinc with hydroxychloroquine). The rapid and persistent contributions of researchers from around the world during the spread of COVID-19 have led to numerous successful treatments. Several antiviral medications, anti-inflammatory medications, antibodies, corticosteroids and convalescent plasmas have been suggested for the treatment of COVID-19, thus far, although truly effective medications are still being tested. The purpose of this review is to give an overview of current developments in metal pharmacology-based COVID-19 therapy methods and the brief introduction to the usage of metal and metal-based medications currently and in the future.
No takes yet. Share an insight, caveat, or question.
Iqbal et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: